- $613.47m
- $365.28m
- 44
- 24
- 65
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.24 | ||
| Price to Tang. Book | 2.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.03% | ||
| Return on Equity | -36.41% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.12 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Directors
- Ali Behbahani NEC (44)
- Paul Hastings PRE (61)
- Nadir Mahmood CFO (41)
- Ralph Brandenberger SVP (52)
- James Trager CSO (58)
- Kanya Rajangam OTH (47)
- Alicia Hager SEC (51)
- Tiba Aynechi IND (45)
- Fouad Azzam IND (54)
- Michael Dybbs IND (46)
- Simeon George IND
- Leone Patterson IND (58)
- Zachary Scheiner IND (44)
- Laura Shawver IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 13th, 2015
- Public Since
- July 10th, 2020
- No. of Shareholders
- 17
- No. of Employees
- 150
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 70,191,295
- Address
- 1150 Veterans Boulevard, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.nkartatx.com/
- Phone
- +1 9254071049
- Auditors
- Ernst & Young LLP
Upcoming Events for NKTX
Nkarta Inc Annual Shareholders Meeting
Q2 2024 Nkarta Inc Earnings Release
Similar to NKTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Nkarta share price?
As of Today at 19:15 UTC, shares in Nkarta are trading at $8.74. This share price information is delayed by 15 minutes.
How has the Nkarta share price performed this year?
Shares in Nkarta last closed at $8.74 and the price had moved by +103.26% over the past 365 days. In terms of relative price strength the Nkarta share price has outperformed the S&P500 Index by +64.15% over the past year.
What are the analyst and broker recommendations for Nkarta?
The overall consensus recommendation for Nkarta is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nkarta dividend yield?
Nkarta does not currently pay a dividend.
Does Nkarta pay a dividend?
Nkarta does not currently pay a dividend.
When does Nkarta next pay dividends?
Nkarta does not currently pay a dividend.
How do I buy Nkarta shares?
To buy shares in Nkarta you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nkarta?
As of the previous close price of $8.74, shares in Nkarta had a market capitalisation of $613.47m.
Where are Nkarta shares listed?
Here are the trading details for Nkarta:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NKTX
What kind of share is Nkarta?
Based on an overall assessment of its quality, value and momentum Nkarta is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nkarta share price forecast for 2024?
The analyst consensus target price for shares in Nkarta is $19.25. That is 120.25% above the last closing price of $8.74.
Analysts covering Nkarta currently have a consensus Earnings Per Share (EPS) forecast of -$2.10 for the next financial year.
What is the trend in the Nkarta share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nkarta. Over the past six months, its share price has outperformed the S&P500 Index by +384.48%.
As of the last closing price of $8.74, shares in Nkarta were trading +72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nkarta PE Ratio?
The Nkarta PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nkarta?
Nkarta's management team is headed by:
- Ali Behbahani - NEC
- Paul Hastings - PRE
- Nadir Mahmood - CFO
- Ralph Brandenberger - SVP
- James Trager - CSO
- Kanya Rajangam - OTH
- Alicia Hager - SEC
- Tiba Aynechi - IND
- Fouad Azzam - IND
- Michael Dybbs - IND
- Simeon George - IND
- Leone Patterson - IND
- Zachary Scheiner - IND
- Laura Shawver - IND